Medscape is available in 5 Language Editions – Choose your Edition here.


Vulvovaginitis Treatment & Management

  • Author: Jill M Krapf, MD, FACOG; Chief Editor: Christine Isaacs, MD  more...
Updated: Mar 30, 2015

Approach Considerations

Vulvovaginal candidiasis

Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC. However, self medication with OTC preparations should be advised only for women who have been diagnosed previously with vulvovaginal candidiasis and who have a recurrence of the same symptoms.

Any woman whose symptoms persist after using an OTC preparation or who has a recurrence of symptoms within 2 months should seek medical care.[32] Unnecessary or inappropriate use of OTC preparations is common and can lead to delayed treatment for other etiologies of vulvovaginitis, possibly causing adverse clinical outcomes. Studies on women treating themselves for candidiasis revealed a 28% accuracy rate.[3]

Vulvar vestibulitis

Considerable controversy exists regarding the optimum mode of treatment for this condition. Many therapeutic regimens have been used with varying success.

Contact dermatitis

Literature is limited on treatment options. Most treatment regimens are empiric and based on clinical experience.


Vulvovaginal Candidiasis

The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.[33]

In considering treatment, distinguishing between sporadic and recurrent episodes of vulvovaginal candidiasis is of great importance. Uncomplicated sporadic vulvovaginal candidiasis usually is caused by strains of C albicans. Most of these strains exhibit sensitivity to azole-based antifungal agents and are therefore usually responsive to all forms of antifungal therapy.

To date, studies have shown no overall difference in the in vitro activity and clinical efficacy of the various azole topical agents, used in the treatment of uncomplicated cases (see Table 1, below). Thus, practitioners can begin with an empiric trial of treatment without relying on cultures. In uncomplicated cases, selection of treatment usually is based on patient preference.

A number of antimycotic regimens are available for the treatment of vulvovaginal candidiasis, including with oral and topical agents. However, drug interactions with oral usage must be taken into consideration. Hepatotoxicity secondary to ketoconazole therapy occurs in approximately 1 in every 10,000-15,000 individuals exposed to this drug. Adverse effects also can include nausea, abdominal pain, and headaches. Drug interactions may occur with simultaneous use of calcium channel antagonists, warfarin, cyclosporine, oral hypoglycemic agents, protease inhibitors, theophylline, and rifampin, to name a few.

In comparative trials of 10- to 14-day courses of therapy, the azoles resulted in higher rates of clinical and mycologic cure (80-95%) than another effective topical agent, nystatin (70-80%). In addition, the azoles have been more efficacious even when given for less than the 14 days required for nystatin.

Table 1. Suggested Treatment Options as Cited in the US Centers for Disease Control and Prevention (CDC) Guidelines for Treatment (Open Table in a new window)

Option Treatment
Butoconazole 2% cream, 5 g intravaginally for 3 days
Butoconazole 2% cream, 5 g (butoconazole 1-sustained release), single intravaginal application
Clotrimazole 1% cream, 5 g intravaginally for 7–14 days
Clotrimazole 100 mg vaginal tablet for 7 days
Clotrimazole 100 mg vaginal tablet, 2 tablets for 3 days
Miconazole 2% cream 5 g intravaginally for 7 days
Miconazole 100 mg vaginal suppository, 1 suppository for 7 days
Miconazole 200 mg vaginal suppository, 1 suppository for 3 days
Miconazole 1200 mg vaginal suppository, 1 suppository for 1 day
Nystatin 100,000-unit vaginal tablet, 1 tablet for 14 days
Tioconazole 6.5% ointment 5 g intravaginally in a single application
Terconazole 0.4% cream 5 g intravaginally for 7 days
Terconazole 0.8% cream 5 g intravaginally for 3 days
Terconazole 80 mg vaginal suppository, 1 suppository for 3 days
Fluconazole 150 mg oral tablet, 1 tablet in single dose

Recurrent vulvovaginal candidiasis

Several studies have shown the effectiveness of antifungal maintenance suppressive therapy for several months. Although an optimal regimen has not yet been established, treatments include ketoconazole (400 mg/day), itraconazole (50-100 mg/day), fluconazole (100 mg/wk for 6 wk), and clotrimazole (500-mg vaginal suppositories once per wk). These regimens have been used for up to 6 months.[2]

Topical boric acid[34] has been used for decades as a treatment for vulvovaginal candidiasis. Although it often is effective, it is classified as a poison and may be absorbed systematically through the vaginal mucosa. For protection, it is encapsulated in a gelatinous capsule and administered as a suppository. Treatment includes 600 mg in size 0 gelatin capsules administered intravaginally every day for 2 weeks.

In addition to medical treatment, studies have shown that ingested sucrose and lactose may support and promote the growth of yeast. Therefore, having patients limit their dietary intake of such sugars may help. Patients are also advised to wear loose-fitting, nonocclusive clothing and cotton underwear to avoid providing the warm, moist climate in which Candida tends to thrive. Some providers recommend washing clothing in hot water and using panty liners to avoid creating a reservoir for the fungus.


Atrophic Vaginitis

Estrogen treatment

Accumulating evidence indicates that the symptoms of atrophic vaginitis readily respond to estrogen therapy. With treatment, mucosal thickening with glandular function can be maintained well into the postmenopausal period. Estrogen’s effect on vaginal cytology is quantified with the maturation index, using vaginal smears from the lateral walls of the upper one third of the vagina.[35, 36]

Treatment usually entails the use of topical vaginal estrogen for 1-2 weeks to alleviate symptoms. An increase in superficial cells and the vaginal maturation index occurs at levels of plasma estrogen that are barely above those of menopause. Once symptoms improve, continuation of treatment at decreased intervals is necessary for maintenance. An oral estrogen regimen can also be used.

Studies demonstrate that vaginal creams produce serum estradiol levels one-fourth those of oral estrogen but are 4-times more potent than oral estrogen on the vagina. Treatment can be continued indefinitely, although safety data for treatment beyond 1 year have not been established.

The choice of modality for local estrogen administration should be guided by patient preference, taking into account factors such as cost and convenience. A systematic review of 16 randomized trials investigating local estrogen treatment of vaginal atrophy found that creams, pessaries, and rings were all similarly effective in relieving the symptoms.[37]

Numerous studies have used different treatment regimens; treatment usually is selected based on clinician preference. The manufacturers of Premarin vaginal conjugated estrogen cream suggest 0.5-2 g applied 3-7 times per week for 3 weeks, followed by 1 week without, for 3-6 months.

Estrogen cream

The advantages of vaginal estrogen cream include lower plasma levels and greater effectiveness than with oral treatment. Disadvantages include compliance issues due to the application process itself and its messiness; as a result, the silastic vaginal ring (Estring) and vaginal tablets (Vagifem) were developed.

Vaginal ring

The vaginal ring is placed in the vagina to release small, controlled doses of estrogen daily (7.5 mcg of estradiol).[38] Serum estrogen is slightly increased but usually remains in the menopausal range. The ring has been noted to have at least equal efficacy to vaginal estrogen cream with regard to tissue integrity and patient acceptance. It is intended to be used continuously for 90 days and can be used during sexual intercourse.[39]

Vaginal tablet

Vagifem, a vaginal tablet containing 25 g of 17-beta estradiol, has been demonstrated to be well tolerated and effective. In a 12-week, double-blind, randomized, placebo-controlled study by Eriksen et al, greater symptom improvement was seen with Vagifem than with placebo. Treatment is clinician-based, with a common regimen being 1 tablet daily followed by a twice-weekly maintenance application.[40]

Health concerns

Studies, although short-term, have not demonstrated an association between the use of unopposed estrogen and the risk of endometrial proliferation and possible subsequent endometrial carcinoma. Estradiol levels in the range of less than 70 pmol/L have been shown to be associated with atrophy of the endometrium. These forms of estrogen all maintain plasma levels well below 30 pmol/L during steady state.

In a study of 60 postmenopausal women randomly assigned to receive Estring or no treatment for 12 months, no significant increases in endometrial thickness were observed in either group. Similar results have been reported with estrogen vaginal tablets. Thus, the risk of endometrial carcinoma is considered minimal. However, any amount of estrogen absorption may be clinically relevant in a patient with breast cancer.[37]

Alternative treatments

Hormone therapy is not the only option for postmenopausal women with atrophic vaginitis. Women who cannot or do not want to take hormones may decide to use nonpharmacologic therapies, such as herbal treatments. However, although herbal treatments are used widely by women—a survey by the North American Menopause Society indicated that up to 10% of women use herbal therapies for menopausal symptoms—they remain largely unstudied by the scientific community.[41] Three agents that have been under study are dong quai, black cohosh, and isoflavones.

Dong quai

Many women in Europe and the United States have used dong quai, a traditional Chinese herb extracted from the Angelica sinensis root, for menopausal symptoms. Although US and European women use this herb alone, Chinese practitioners prescribe it in conjunction with other herbs.

In a study in which 71 women with hot flashes were given either dong quai (4.5 g daily) or placebo for 6 months, no difference in endometrial thickness or in the vaginal maturation index was found between the 2 groups. Dermatitis secondary to photosensitization is a common adverse effect of this drug.[42]

Black cohosh

Black cohosh (Cimicifuga racemosa) is marketed as a precursor of progesterone that has estrogenlike effects. It is a phytoestrogen that contains triterpene, a flavonoid, and has been used in Germany for decades to treat menopausal symptoms. Black cohosh has been found to reduce levels of luteinizing hormone, but not follicle-stimulating hormone, in menopausal women. According to a few studies, extract doses of either 2 tablets or 40 drops twice daily can safely reduce menopausal symptoms. Data are limited, however, and no information is available on toxicity. In rare cases, black cohosh can cause stomach upset. It has an additive hypotensive effect when combined with antihypertensives. The recommended dosage is for a maximum duration of 6 months.[43]


Phytoestrogens are naturally occurring plant sterols that have estrogenic and antiestrogenic effects in humans. They include isoflavones (found in soybeans), coumestans (found in red clover and alfalfa sprouts), and lignans (found in oil seeds such as flaxseed).

Phytoestrogens are absorbed and converted by the intestinal flora into compounds that resemble estrogen. They then bind with and activate human estrogen receptors. If endogenous estrogen levels are high, they exhibit antiestrogenic effects; however, in postmenopausal women in whom levels are diminished, they are found to exhibit estrogenic properties.[44]

Interest in isoflavones escalated after observation that Asian women, who consume a much higher quantity of isoflavones than do Western women, experience fewer menopausal symptoms. A small study of menopausal Thai women demonstrated that only 27% of them reported menopausal vasomotor symptoms, as opposed to 85% of Western women.[45]

Studies, although limited, have demonstrated small increases in vaginal superficial cells with the ingestion of isoflavone. However, no significant increase in follicle-stimulating hormone or luteinizing hormone has been demonstrated.

Additional therapies

Other nonhormonal therapies include vaginal moisturizers and lubricants.[46] The lubricant is used just before intercourse, and the moisturizer is used long-term to relieve symptoms. Nachtigall et al compared the effect of a moisturizer (Replens) with that of conjugated estrogen cream (Premarin) in a randomized 12-week trial with 30 patients and found that, although both agents were effective, estrogen therapy was more effective in restoring vaginal elasticity and reversing vaginal atrophy. Replens was administered 3 times weekly with an applicator, and the cream was used at 1.25 mg/day.[35]

The results demonstrated that both produced lower pH levels; however, the estrogen produced a statistically significantly greater effect on vaginal elasticity within 4 weeks. The Replens increased elasticity over a longer period of time. It also reversed vaginal atrophy in 60% of patients, compared with 100% of patients receiving estrogen.


Vulvar Vestibulitis

Of the treatments listed here for vulvar vestibulitis, most have not been evaluated prospectively and are based on clinical experiences reported in the literature.

Generally, no specific cure is available for this disorder, but spontaneous resolution has been reported; thus, treatment should focus on the alleviation of symptoms. Pain management has consisted of modalities such as sex therapy, behavior modification,[47] biofeedback,[47] and acupuncture.

Remedies that have been used with some success include topical application of anesthetics, such as 5% Xylocaine ointment, applied 15-30 minutes prior to intercourse. Other treatments include the use of a protective coating, such as from petroleum jelly or vitamin A and D ointment (to minimize contact with any irritating vaginal discharges); topical corticosteroids; wet compresses with aluminum acetate; and anti-inflammatory agents.

A case report by Solomons demonstrated the use of oral calcium citrate combined with a low oxalate diet. He noted that calcium oxalate crystals released in urine might act as an irritant in the development of vulvar vestibulitis. He recommended a low oxalate diet with the ingestion of calcium citrate (200 mg calcium and 950 mg citrate) to theoretically inhibit the formation of calcium oxalate crystals.[48] Many other authors have also recommend this trial of treatment; however, studies are lacking with regard to benefit.

A number of trials have used alpha interferon and have noted some success with it. The idea of using this agent against vulvar vestibulitis was initiated after alpha interferon was used successfully in the treatment of condylomata acuminata. Horowitz et al treated 17 women with severe vulvar vestibulitis with intravestibular injections of alpha interferon, administering 1 million units 3 times per week for 1 month.

The investigators noted that 15 of the 17 women demonstrated considerable improvement. Favorable response was gauged by improvement of clinical symptoms, such as dyspareunia.[49] However, recommendations at this time indicate that alpha interferon should be used as a mode of treatment for women who present with concomitant HPV infections.

Because the etiology of pain in vulvar vestibulitis is neuropathic, research has focused on pharmacologic treatment that addresses neuropathic pain. Medications such as gabapentin and pregabalin have been used with success. In a study of 152 women with vulvar pain treated with gabapentin, 98 (64%) achieved resolution of at least 80% of their symptoms.[50]


Surgical excision may be considered as a last resort in the treatment of vulvar vestibulitis. Woodruff and Parmley developed the original surgical mode of treatment, describing a U-shaped excision of the posterior hymenal ring 0.5 cm on each side of the hymen, starting 0.5 cm below the urethra on each side. In their study, they reported that women who fulfilled the criteria of vulvar vestibulitis who underwent surgery demonstrated a success rate of 80%.[12] Most other studies have reported success rates of 60%. Postoperative complications, although uncommon, include dehiscence, hematoma, infection, uneven healing, and nodular excrescences along the suture line.

In the 1980s, excision by carbon dioxide laser microsurgery of the Bartholin gland or glands, followed by excision of the vestibular tissue, was used in an attempt to relieve pain thought to be caused by HPV. Healing was noted to be prolonged, and complications such as scarring and further pain led to the general abandonment of this technique.


Contact Dermatitis

The first step towards treatment of contact dermatitis is removal of the inciting agent. Patch testing may be necessary for allergen identification. Avoidance of sexual intercourse, douching, detergents, soaps, and perfumes is essential. Mild vulvovaginal reactions usually subside rapidly after the causative agent is withdrawn.

Cleansing can be accomplished by gentle flushing of the area once daily with clear water and patting the area dry. Triamcinolone ointment (0.1%) applied twice daily can help in irritant contact dermatitis. Severe lesions can be treated with wet compresses of aluminum acetate solution for 30 minutes several times per day. After each application, the vulvar skin must be kept clean and dry.

Hydrocortisone (0.5-1%) and fluorinated corticosteroids in lotions or creams may help to reduce symptoms; they are usually most beneficial in the treatment of true allergic reactions. Additional treatment can include antihistamines and sodium bicarbonate sitz baths.

Contributor Information and Disclosures

Jill M Krapf, MD, FACOG Assistant Professor, Department of Obstetrics and Gynecology, George Washington University School of Medicine and Health Sciences; Assistant Director, Obstetrics and Gynecology Clerkship, Center for Sexual Health, Women’s Services

Jill M Krapf, MD, FACOG is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Medical Association, Association of Professors of Gynecology and Obstetrics, American Congress of Obstetricians and Gynecologists, International Society for the Study of Women’s Sexual Health

Disclosure: Nothing to disclose.

Specialty Editor Board

Nicole W Karjane, MD Associate Professor, Department of Obstetrics and Gynecology, Virginia Commonwealth University Medical Center

Nicole W Karjane, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, Association of Professors of Gynecology and Obstetrics, North American Society for Pediatric and Adolescent Gynecology

Disclosure: Nothing to disclose.

Chief Editor

Christine Isaacs, MD Associate Professor, Department of Obstetrics and Gynecology, Division Head, General Obstetrics and Gynecology, Medical Director of Midwifery Services, Virginia Commonwealth University School of Medicine

Christine Isaacs, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists

Disclosure: Nothing to disclose.


Pamela L Dyne, MD Professor of Clinical Medicine/Emergency Medicine, University of California, Los Angeles, David Geffen School of Medicine; Attending Physician, Department of Emergency Medicine, Olive View-UCLA Medical Center

Pamela L Dyne, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

David S Howes, MD Professor of Medicine and Pediatrics, Emergency Medicine Residency Program Director Emeritus, Head, Phemister Society, University of Chicago Division of the Biological Sciences, The Pritzker School of Medicine

David S Howes, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Reza Keshavarz, MD, MPH Clinical Assistant Professor, Departments of Pediatrics and Emergency Medicine, Mount Sinai School of Medicine; Director of Pediatric Emergency Medicine, Mount Sinai Hospital

Disclosure: Nothing to disclose.

Mark J Leber, MD, MPH Assistant Professor of Emergency Medicine in Clinical Medicine, Weill Cornell Medical College; Attending Physician, Lincoln Medical and Mental Health Center

Mark J Leber, MD, MPH is a member of the following medical societies: American College of Emergency Physicians and American College of Physicians

Disclosure: Nothing to disclose.

Deslyn M Mancini, MD Instructor, Department of Obstetrics and Gynecology, MCP Hahnemann University

Disclosure: Nothing to disclose.

Bruce A Meyer, MD, MBA Executive Vice President for Health System Affairs, Executive Director, Faculty Practice Plan, Professor, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical School

Bruce A Meyer, MD, MBA is a member of the following medical societies: American College of Obstetricians and Gynecologists, American College of Physician Executives, American Institute of Ultrasound in Medicine, Association of Professors of Gynecology and Obstetrics, Massachusetts Medical Society, Medical Group Management Association, and Society for Maternal-Fetal Medicine

Disclosure: Nothing to disclose.

Omnia M Samra-Latif, MD Clinical Faculty, Department of Obstetrics and Gynecology, Robert Wood Johnson University, Hamilton Hospital

Omnia M Samra-Latif, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists and American Medical Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Anuritha Tirumani, MD Research Coordinator, Department of Emergency Medicine, Brooklyn Hospital Center

Disclosure: Nothing to disclose.

Ellen Wood, DO, FACOOG Voluntary Assistant Professor, University of Miami, Leonard M Miller School of Medicine

Ellen Wood, DO, FACOOG is a member of the following medical societies: American Society for Reproductive Medicine

Disclosure: Nothing to disclose.

Mark Zwanger, MD, MBA Assistant Professor, Department of Emergency Medicine, Jefferson Medical College of Thomas Jefferson University

Mark Zwanger, MD, MBA is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, and American Medical Association

Disclosure: Nothing to disclose.

  1. Chatwani AJ, Mehta R, Hassan S, Rahimi S, Jeronis S, Dandolu V. Rapid testing for vaginal yeast detection: a prospective study. Am J Obstet Gynecol. 2007 Apr. 196(4):309.e1-4. [Medline].

  2. Donders G, Bellen G, Byttebier G, Verguts L, Hinoul P, Walckiers R, et al. Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial). Am J Obstet Gynecol. 2008 Dec. 199(6):613.e1-9. [Medline].

  3. Katz. Vaginitis. Katz. Comprehensive Gynecology. 5th ed. Mosby; Elsevier; 2007. 588-596.

  4. Horowitz BJ, Edelstein SW, Lippman L. Sexual transmission of Candida. Obstet Gynecol. 1987 Jun. 69(6):883-6. [Medline].

  5. Ip WK, Lau YL. Role of mannose-binding lectin in the innate defense against Candida albicans: enhancement of complement activation, but lack of opsonic function, in phagocytosis by human dendritic cells. J Infect Dis. 2004 Aug 1. 190(3):632-40. [Medline].

  6. Lillegard JB, Sim RB, Thorkildson P, Gates MA, Kozel TR. Recognition of Candida albicans by mannan-binding lectin in vitro and in vivo. J Infect Dis. 2006 Jun 1. 193(11):1589-97. [Medline].

  7. Liu F, Liao Q, Liu Z. Mannose-binding lectin and vulvovaginal candidiasis. Int J Gynaecol Obstet. 2006 Jan. 92(1):43-7. [Medline].

  8. Giraldo PC, Babula O, Gonçalves AK, Linhares IM, Amaral RL, Ledger WJ, et al. Mannose-binding lectin gene polymorphism, vulvovaginal candidiasis, and bacterial vaginosis. Obstet Gynecol. 2007 May. 109(5):1123-8. [Medline].

  9. Fong IW. The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourin Med. 1992 Jun. 68(3):174-6. [Medline]. [Full Text].

  10. Pandit L, Ouslander JG. Postmenopausal vaginal atrophy and atrophic vaginitis. Am J Med Sci. 1997 Oct. 314(4):228-31. [Medline].

  11. Pyka RE, Wilkinson EJ, Friedrich EG Jr, Croker BP. The histopathology of vulvar vestibulitis syndrome. Int J Gynecol Pathol. 1988. 7(3):249-57. [Medline].

  12. Woodruff JD, Parmley TH. Infection of the minor vestibular gland. Obstet Gynecol. 1983 Nov. 62(5):609-12. [Medline].

  13. Bergeron C, Moyal-Barracco M, Pelisse M, Lewin P. Vulvar vestibulitis. Lack of evidence for a human papillomavirus etiology. J Reprod Med. 1994 Dec. 39(12):936-8. [Medline].

  14. Turner ML, Marinoff SC. Association of human papillomavirus with vulvodynia and the vulvar vestibulitis syndrome. J Reprod Med. 1988 Jun. 33(6):533-7. [Medline].

  15. Marinoff SC, Turner ML. Vulvar vestibulitis syndrome. Dermatol Clin. 1992 Apr. 10(2):435-44. [Medline].

  16. Westrom LV, Willen R. Vestibular nerve fiber proliferation in vulvar vestibulitis syndrome. Obstet Gynecol. 1998 Apr. 91(4):572-6. [Medline].

  17. Szumigala JA, Alveredo R. Vulvovaginitis. Ferri. Ferri's Clinical Advisor 2009. Mosby; Elsevier; 2009. 155, 1008-1012.

  18. Eckert LO. Clinical practice. Acute vulvovaginitis. N Engl J Med. 2006 Sep 21. 355(12):1244-52. [Medline].

  19. Margesson LJ. Vulvar disease pearls. Dermatol Clin. 2006 Apr. 24(2):145-55, v. [Medline].

  20. Foxman B, Muraglia R, Dietz JP, Sobel JD, Wagner J. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J Low Genit Tract Dis. 2013 Jul. 17(3):340-5. [Medline].

  21. Nyirjesy P. Vulvovaginal candidiasis and bacterial vaginosis. Infect Dis Clin North Am. 2008 Dec. 22(4):637-52, vi. [Medline].

  22. Braverman PK. Urethritis, vulvovaginitis, and cervicitis. Principles and Practice of Pediatric Infectious Diseases. 3rd ed. Churchill Livingstone; Elsevier; 2008. 55.

  23. Biggs WS, Williams RM. Common gynecologic infections. Prim Care. 2009 Mar. 36(1):33-51, viii. [Medline].

  24. Johnson E, Berwald N. Evidence-based emergency medicine/rational clinical examination abstract. Diagnostic utility of physical examination, history, and laboratory evaluation in emergency department patients with vaginal complaints. Ann Emerg Med. 2008 Sep. 52(3):294-7. [Medline].

  25. Nyirjesy P, Leigh RD, Mathew L, Lev-Sagie A, Culhane JF. Chronic vulvovaginitis in women older than 50 years: analysis of a prospective database. J Low Genit Tract Dis. 2012 Jan. 16(1):24-9. [Medline].

  26. Halperin R, Zehavi S, Vaknin Z, Ben-Ami I, Pansky M, Schneider D. The major histopathologic characteristics in the vulvar vestibulitis syndrome. Gynecol Obstet Invest. 2005. 59(2):75-9. [Medline].

  27. Esim Buyukbayrak E, Kars B, Karsidag AY, Karadeniz BI, Kaymaz O, Gencer S, et al. Diagnosis of vulvovaginitis: comparison of clinical and microbiological diagnosis. Arch Gynecol Obstet. 2010 Nov. 282(5):515-9. [Medline].

  28. Schwiertz A, Taras D, Rusch K, Rusch V. Throwing the dice for the diagnosis of vaginal complaints?. Ann Clin Microbiol Antimicrob. 2006 Feb 17. 5:4. [Medline]. [Full Text].

  29. [Guideline] Workowski KA, Berman S. Sexually Transmitted Diseases Treatment Guidelines, 2010. MMWR. Dec 17 2010;59(RR-12). Centers for Disease Control and Prevention. Available at Accessed: August 22, 2013.

  30. Ferris DG, Francis SL, Dickman ED, Miler-Miles K, Waller JL, McClendon N. Variability of vaginal pH determination by patients and clinicians. J Am Board Fam Med. 2006 Jul-Aug. 19(4):368-73. [Medline].

  31. Kulp JL, Chaudhry S, Wiita B, Bachmann G. The accuracy of women performing vaginal pH self-testing. J Womens Health (Larchmt). 2008 May. 17(4):523-6. [Medline].

  32. [Guideline] Huntzinger A. Guideline Briefs. Practice American Family Physician. Nov 2006. 74.

  33. Sobel JD, Wiesenfeld HC, Martens M, Danna P, Hooton TM, Rompalo A, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med. 2004 Aug 26. 351(9):876-83. [Medline].

  34. Sobel JD, Chaim W. Treatment of Torulopsis glabrata vaginitis: retrospective review of boric acid therapy. Clin Infect Dis. 1997 Apr. 24(4):649-52. [Medline].

  35. Nachtigall LD. Use of low-dose premarin, estrace, and estring vaginally. Obstetrical and Gynecological Survey. 1998. 53(10S):62S-65S.

  36. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2006 Oct 18. CD001500. [Medline].

  37. The North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause. 2007 May-Jun. 14(3 pt 1):355-69; quiz 370-1. [Medline].

  38. Henriksson L, Stjernquist M, Boquist L, Cedergren I, Selinus I. A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol. 1996 Jan. 174(1 Pt 1):85-92. [Medline].

  39. Ayton RA, Darling GM, Murkies AL, Farrell EA, Weisberg E, Selinus I, et al. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br J Obstet Gynaecol. 1996 Apr. 103(4):351-8. [Medline].

  40. Eriksen PS, Rasmussen H. Low-dose 17 beta-estradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study. Eur J Obstet Gynecol Reprod Biol. 1992 Apr 21. 44(2):137-44. [Medline].

  41. Brossfield J. Herbal Therapies for Menopause. The Resident Reporter. 2000. 5(6):26-30.

  42. Hirata JD, Swiersz LM, Zell B, Small R, Ettinger B. Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. Fertil Steril. 1997 Dec. 68(6):981-6. [Medline].

  43. Lieberman S. A review of the effectiveness of Cimicifuga racemosa (black cohosh) for the symptoms of menopause. J Womens Health. 1998 Jun. 7(5):525-9. [Medline].

  44. Nachtigall LB, LaGrega L, Lee WW. The effects of isoflavones derived from red clover on vasomotor symptoms and endometrial thickness. 9th International Menopause Society World Congress on Menopause. 1999.

  45. Punyahotra S, Dennerstein L, Lehert P. Menopausal experiences of Thai women. Part 1: Symptoms and their correlates. Maturitas. 1997 Jan. 26(1):1-7. [Medline].

  46. Chen J, Geng L, Song X, Li H, Giordan N, Liao Q. Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel-group, clinical trial. J Sex Med. 2013 Jun. 10(6):1575-84. [Medline].

  47. Bergeron S, Binik YM, Khalifé S, Pagidas K. Vulvar vestibulitis syndrome: a critical review. Clin J Pain. 1997 Mar. 13(1):27-42. [Medline].

  48. Solomons CC, Melmed MH, Heitler SM. Calcium citrate for vulvar vestibulitis. A case report. J Reprod Med. 1991 Dec. 36(12):879-82. [Medline].

  49. Horowitz BJ. Interferon therapy for condylomatous vulvitis. Obstet Gynecol. 1989 Mar. 73(3 Pt 1):446-8. [Medline].

  50. Harris G, Horowitz B, Borgida A. Evaluation of gabapentin in the treatment of generalized vulvodynia, unprovoked. J Reprod Med. 2007 Feb. 52(2):103-6. [Medline].

  51. Marrazzo J. Vulvovaginal candidiasis. BMJ. 2002 Sep 14. 325(7364):586. [Medline]. [Full Text].

Candida albicans photomicrograph. Courtesy of Centers for Disease Control and Prevention (CDC).
Table 1. Suggested Treatment Options as Cited in the US Centers for Disease Control and Prevention (CDC) Guidelines for Treatment
Option Treatment
Butoconazole 2% cream, 5 g intravaginally for 3 days
Butoconazole 2% cream, 5 g (butoconazole 1-sustained release), single intravaginal application
Clotrimazole 1% cream, 5 g intravaginally for 7–14 days
Clotrimazole 100 mg vaginal tablet for 7 days
Clotrimazole 100 mg vaginal tablet, 2 tablets for 3 days
Miconazole 2% cream 5 g intravaginally for 7 days
Miconazole 100 mg vaginal suppository, 1 suppository for 7 days
Miconazole 200 mg vaginal suppository, 1 suppository for 3 days
Miconazole 1200 mg vaginal suppository, 1 suppository for 1 day
Nystatin 100,000-unit vaginal tablet, 1 tablet for 14 days
Tioconazole 6.5% ointment 5 g intravaginally in a single application
Terconazole 0.4% cream 5 g intravaginally for 7 days
Terconazole 0.8% cream 5 g intravaginally for 3 days
Terconazole 80 mg vaginal suppository, 1 suppository for 3 days
Fluconazole 150 mg oral tablet, 1 tablet in single dose
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.